Microbot Medical (MBOT) Cash & Equivalents (2010 - 2026)

Microbot Medical (MBOT) has 17 years of Cash & Equivalents data on file, last reported at $200000.0 in Q1 2026.

• Quarterly Cash & Equivalents fell 99.26% year-over-year to $200000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $200000.0 (down 99.26% YoY) and the FY2025 annual result came in at $2000.0, down 99.94% from the prior year.
• Cash & Equivalents rose to $200000.0 in Q1 2026, from $2000.0 in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $28.6 million in Q2 2025 to a low of $2000.0 in Q4 2025.
• A 5-year average of $5.2 million and a median of $1.3 million in 2023 frame the typical range for Cash & Equivalents.
• The widest YoY moves for Cash & Equivalents: up 56510.42% in 2025, down 99.94% in 2025.
• Tracing MBOT's Cash & Equivalents over 5 years: stood at $2.4 million in 2022, then slumped by 97.99% to $49000.0 in 2023, then jumped by 6255.1% to $3.1 million in 2024, then tumbled by 99.94% to $2000.0 in 2025, then soared by 9900.0% to $200000.0 in 2026.
• The last three Cash & Equivalents figures came in at $200000.0 (Q1 2026), $2000.0 (Q4 2025), and $54000.0 (Q3 2025), per Business Quant data.